Takara Bio Inc. released its earnings results on Nov 11, 2025. The company reported -¥44.85 earnings per share for the quarter, missing the consensus estimate of N/A by -¥44.85.

Is Takara Bio Inc. overvalued?

According to Wall Street analysts Takara Bio Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Takara Bio Inc. pay dividends?

Takara Bio Inc. pays a Annually dividend of ¥17 which represents an annual dividend yield of 2.2%. See more information on Takara Bio Inc. dividends here

What is Takara Bio Inc.’s EPS estimate?

Takara Bio Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Takara Bio Inc. have?

Takara Bio Inc. has 120,415,600 shares outstanding.

What happened to Takara Bio Inc.’s price movement after its last earnings report?

Takara Bio Inc. reported an EPS of -¥44.85 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.333%.

Which hedge fund is a major shareholder of Takara Bio Inc.?

Currently, no hedge funds are holding shares in JP:4974

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Takara Bio Inc.

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.